Chinese Covid-19 vaccine manufacturer Sinovac announced that the vaccine they developed can trigger immune responses in children and adolescents.
Preliminary data were obtained from Phase I and II clinical trials involving more than 500 people aged 3 to 17 years, while individuals were injected with a medium or low dose of two doses of Covid-19 vaccine or a dose of placebo.
Most adverse reactions in children and adolescents with the Covid-19 vaccine are mild, company researcher Zeng Gang said at an academic conference in Beijing.
In a study of more than 500 people, Gang reported that only two children who took low doses suffered from high fever, classified as grade 3.
MORE ANTIBODY LEVEL MEASURED THAN THOSE AGES OVER 18
In his presentation at the academic conference, Gang said antibody levels triggered by the CoronaVac vaccine were higher than those seen in adults aged 18 to 59 and the elderly in previous clinical studies.
Gang reported that administration of a lower dose of vaccine gives better results for children aged 3 to 11 years, and that administration of medium doses of vaccine gave good results for people aged 12 to 17 years.
It was stated that the preliminary data announced by Sinovac have not yet been published in a peer-reviewed medical journal.